Skip to content

Response to pneumococcal polysaccharide vaccination in healthy adults

Response to pneumococcal polysaccharide vaccination in healthy adults - Pneumococcal vaccination in healthy adults

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55592
Enrollment
210
Registered
2019-07-18
Start date
2020-01-01
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

specific antibody deficiency

Interventions

One-time administration of the 23-valent pneumococcal polysaccharide vaccine.

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age >=18 years and

Exclusion criteria

Exclusion criteria: • Previous vaccination with pneumococcal polysaccharide or conjugate vaccination • Chronic disease that requires the use of immunosuppressive agents • Known or highly suspected primary or secondary immunodeficiency • Pregnancy • Fever or active infection • History of allergic reaction to one of the vaccine components

Design outcomes

Primary

MeasureTime frame
Distribution of serotype-specific IgG antibody titers to 13 pneumococcal serotypes four weeks after vaccination.

Secondary

MeasureTime frame
Distribution of serotype-specific IgG antibody titers to 13 pneumococcal serotypes eight weeks after vaccination. Distribution of serotype-specific IgG1, IgG2, IgM and IgA antibody titers to 13 pneumococcal serotypes four and eight weeks after vaccination. Distribution of serotype-specific percent change in IgG, IgG1, IgG2, IgM and IgA antibody titers to 13 pneumococcal serotypes four and eight weeks after vaccination in comparison to pre-vaccination.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)